CNBC's Meg Tirrell reports on the companies that are working to fight the Zika virus. » Read More
Amid the wreckage in the retail sector, is now the time to cherry-pick some of the names that may have been unfairly punished?
U.S. stocks closed lower, under pressure from disappointing Disney and Macy's earnings, amid sharp gains in oil following a surprise inventory draw.
Biotech stocks dragged on the market Friday, and some "Fast Money" traders contended the pain may not be done.
Gilead Sciences fell nearly 8 percent, dragging down the S&P 500’s health care sector.
The "Fast Money" traders get into biotech and give you 5 trades in a mixed sector.
U.S. stocks closed lower as health care stocks weighed, but the major averages pared losses significantly for the Dow and S&P to post monthly gains.
Mark Spellman, Co-Portfolio Manager at Alpine Funds, talks about some of the companies that have recently raised their dividends.
Some of the names on the move ahead of the open.
Check out the companies making headlines after the bell: Amazon, LinkedIn, Gilead Sciences, Pandora and more.
Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.
CNBC's Meg Tirrell reports Gilead Sciences' quarterly results.
Options trader Dan Nathan says the biotech sector could get a boost on earnings.
The pharmacy benefits manager is looking to partner with retail pharmacies that do the best job at keeping diabetes patients healthy.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 5 stocks with analyst recommendations, including two positive calls on L Brands, and Raymond James reiterating its outperform on Bloomin' Brands.
Predictions are based on trends in revisions activity, growth expectations and historical beat rates, Estimize reports.
Sustainable investing is up 60 percent in the past year, BlackRock estimates.
Is it time to buy biotech as the sector is breaking out?
The "Fast Money" traders give you 4 names to buy in biotech on new inversion rule.
Les Funtleyder, E Squared Asset Management Portfolio Manager, and David Seaburg, Cowen & Company Managing Director and Head of Sales & Trading, discuss the biotech sector and how investors should approach it.
CNBC's Dom Chu looks at stocks that were among the biggest losers in the first quarter.